Features of relapse and type of salvage therapy in 240 patients participating in the PETAL trial
| . | Type of salvage therapy∗ . | P . | |||
|---|---|---|---|---|---|
| Supportive care . | Chemotherapy, immunotherapy, and/or radiotherapy . | Autologous transplantation . | Allogeneic transplantation . | ||
| Number of patients | 16 | 127 | 69 | 28 | |
| Interval to first relapse, y (range) | 0.8 (0.1-8.3) | 0.8 (0.0-14.1) | 0.9 (0.2-10.4) | 0.6 (0.1-6.5) | .508† |
| Age at first relapse, y (range) | 74 (50-82) | 68 (23-86) | 58 (25-76) | 46 (21-67) | <.001† |
| Type of treatment failure leading to first relapse | |||||
| Progression on therapy (refractoriness) | 3 (18.8%) | 30 (23.6%) | 15 (21.7%) | 6 (21.4%) | .967‡ |
| Relapse after remission | 13 (81.2%) | 97 (76.4%) | 54 (78.3%) | 22 (78.6%) | |
| Disease stage at first relapse | |||||
| I | 1 (6.3%) | 12 (9.4%) | 12 (17.4%) | 0 (0.0%) | .1467‡ |
| II | 1 (6.3%) | 15 (11.8%) | 12 (17.4%) | 6 (21.4%) | |
| III | 2 (12.5%) | 16 (12.6%) | 11 (15.9%) | 8 (28.6%) | |
| IV | 8 (50.0%) | 61 (48.1%) | 23 (33.3%) | 11 (39.3%) | |
| Unknown | 4 (25.0%) | 23 (18.1%) | 11 (15.9%) | 3 (10.7%) | |
| . | Type of salvage therapy∗ . | P . | |||
|---|---|---|---|---|---|
| Supportive care . | Chemotherapy, immunotherapy, and/or radiotherapy . | Autologous transplantation . | Allogeneic transplantation . | ||
| Number of patients | 16 | 127 | 69 | 28 | |
| Interval to first relapse, y (range) | 0.8 (0.1-8.3) | 0.8 (0.0-14.1) | 0.9 (0.2-10.4) | 0.6 (0.1-6.5) | .508† |
| Age at first relapse, y (range) | 74 (50-82) | 68 (23-86) | 58 (25-76) | 46 (21-67) | <.001† |
| Type of treatment failure leading to first relapse | |||||
| Progression on therapy (refractoriness) | 3 (18.8%) | 30 (23.6%) | 15 (21.7%) | 6 (21.4%) | .967‡ |
| Relapse after remission | 13 (81.2%) | 97 (76.4%) | 54 (78.3%) | 22 (78.6%) | |
| Disease stage at first relapse | |||||
| I | 1 (6.3%) | 12 (9.4%) | 12 (17.4%) | 0 (0.0%) | .1467‡ |
| II | 1 (6.3%) | 15 (11.8%) | 12 (17.4%) | 6 (21.4%) | |
| III | 2 (12.5%) | 16 (12.6%) | 11 (15.9%) | 8 (28.6%) | |
| IV | 8 (50.0%) | 61 (48.1%) | 23 (33.3%) | 11 (39.3%) | |
| Unknown | 4 (25.0%) | 23 (18.1%) | 11 (15.9%) | 3 (10.7%) | |
Salvage therapy was defined on the basis of the entire disease course after first relapse, including (1) supportive care alone; (2) chemotherapy, immunotherapy, and/or radiotherapy with or without supportive care, but without transplantation; (3) high-dose chemotherapy with auto-SCT with or without chemotherapy, immunotherapy, radiotherapy, or supportive care, but without allogeneic transplantation; and (4) allogeneic transplantation with or without autologous transplantation, chemotherapy, immunotherapy, radiotherapy, or supportive care. Chemotherapy/immunotherapy alone, radiotherapy alone, and chemotherapy/immunotherapy consolidated by radiotherapy were combined in 1 group, because outcome after first relapse did not significantly differ among these modalities (supplemental Figure 5).
Kruskal-Wallis test.
χ2 test.